Hepatitis E Diagnostic Tests Market By Test Type (Immunoassays, PCR Tests, Enzyme-Linked Immunosorbent Assay (ELISA), Lateral Flow Assays), By End-User (Hospitals, Diagnostic Laboratories, Research Institutions, Blood Banks), By Application (Diagnostic Testing, Blood Screening, Clinical Trials, Research Studies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Hepatitis E Diagnostic Tests Market was valued at USD 0.8 billion in 2024-e and will surpass USD 1.5 billion by 2030; growing at a CAGR of 10.9% during 2025 - 2030.

The hepatitis E diagnostic tests market is experiencing significant growth due to the increasing prevalence of hepatitis E infections globally, particularly in developing regions. Hepatitis E is a viral infection that affects the liver and is transmitted through the consumption of contaminated water or food. The rising awareness about the importance of early diagnosis and improved testing methods is driving demand for effective diagnostic solutions. With the increasing burden of hepatitis E in countries with limited healthcare infrastructure, accurate and rapid diagnostic tests are becoming essential to control the spread of the disease and manage public health effectively.

As the global focus on infectious diseases intensifies, the hepatitis E diagnostic tests market is also benefiting from technological advancements in diagnostic methodologies. The introduction of more sensitive and rapid testing techniques, such as PCR tests and enzyme-linked immunosorbent assays (ELISA), is enhancing the accuracy and speed of diagnosis. These innovations are not only helping in the early detection of hepatitis E but also contributing to better monitoring and management of outbreaks, particularly in regions with high infection rates.

Type Owing to High Sensitivity and Accuracy

Immunoassays are the leading test type in the hepatitis E diagnostic tests market due to their high sensitivity, accuracy, and relatively simple execution. These tests detect antibodies or antigens specific to the hepatitis E virus (HEV) and provide a rapid means of identifying the presence of infection. Immunoassays, such as enzyme immunoassays (EIAs) and chemiluminescent immunoassays (CIAs), are widely used in both clinical and laboratory settings due to their ability to offer reliable results quickly and efficiently.

The increasing demand for immunoassays is driven by the need for affordable, quick, and non-invasive diagnostic methods that can be deployed in a variety of healthcare settings, including resource-limited regions. Immunoassays are particularly advantageous for routine screening and diagnosis, making them a critical tool in the fight against hepatitis E infections worldwide. With the growing demand for point-of-care diagnostics, immunoassays are expected to maintain their dominant position in the market for hepatitis E testing.

Diagnostic Laboratories Are Leading End-User Owing to Centralized Testing Services

Diagnostic laboratories are the leading end-user segment in the hepatitis E diagnostic tests market, owing to their centralized testing services and capability to process large volumes of samples. These laboratories provide diagnostic testing for various infectious diseases, including hepatitis E, by offering highly accurate and standardized testing protocols. Diagnostic laboratories are essential in confirming hepatitis E cases, especially in regions where outbreaks occur, and they often serve as primary points for disease surveillance and epidemiological studies.

The growth in diagnostic laboratories is fueled by the increasing demand for specialized and accurate testing to detect hepatitis E infections. As the need for timely diagnosis increases, diagnostic laboratories are equipped with advanced technologies such as PCR tests and immunoassays, allowing for faster and more reliable results. These facilities are expected to continue playing a pivotal role in managing hepatitis E outbreaks and improving public health responses globally.

Diagnostic Testing Is Leading Application Owing to Critical Role in Disease Detection

Diagnostic testing is the leading application in the hepatitis E diagnostic tests market, as it plays a critical role in the early detection of hepatitis E infections. Early diagnosis enables prompt treatment and helps reduce the spread of the disease, particularly in high-risk populations. Hepatitis E diagnostic tests are used to confirm the presence of the virus and determine the stage of the infection, guiding clinicians in providing the appropriate treatment and care to patients.

The growing focus on rapid and accurate diagnostic testing for hepatitis E is further driving the adoption of advanced diagnostic technologies. As governments and healthcare organizations intensify their efforts to control hepatitis E outbreaks, the demand for diagnostic testing services is expected to increase, making it a key application in the market.

PCR Tests Are Leading Technology Owing to High Sensitivity and Specificity

PCR tests are the leading technology in the hepatitis E diagnostic tests market due to their high sensitivity and specificity in detecting the hepatitis E virus (HEV). Polymerase chain reaction (PCR) is a molecular technique that amplifies the genetic material of the virus, allowing for the detection of even low amounts of viral RNA in the blood. PCR tests provide highly accurate results, making them the gold standard for confirming active infections and distinguishing between different strains of the virus.

The growing preference for PCR tests is driven by their ability to detect the virus early in the course of infection, even before the body has produced detectable antibodies. As the need for accurate, reliable, and timely diagnostics grows, PCR testing is becoming an essential tool in the fight against hepatitis E, particularly in clinical and research settings.

Asia Pacific Is Fastest Growing Region Owing to High Hepatitis E Prevalence

Asia Pacific is the fastest growing region in the hepatitis E diagnostic tests market, owing to the high prevalence of hepatitis E in countries such as India, China, and several Southeast Asian nations. The region faces significant challenges related to waterborne diseases, with hepatitis E being one of the most prevalent viral infections. The lack of clean water, inadequate sanitation, and limited access to healthcare services in certain areas contribute to the spread of the disease, highlighting the need for effective diagnostic testing solutions.

As the healthcare infrastructure in Asia Pacific improves and the focus on infectious disease control intensifies, the demand for hepatitis E diagnostic tests is expected to rise. Governments and healthcare organizations are increasingly adopting advanced diagnostic methods to monitor and control hepatitis E outbreaks, making Asia Pacific a key market for the growth of hepatitis E diagnostics.

Leading Companies and Competitive Landscape

The hepatitis E diagnostic tests market is competitive, with leading companies such as Abbott Laboratories, Roche Diagnostics, and Bio-Rad Laboratories at the forefront. These companies are known for their expertise in immunoassays and molecular diagnostics, offering a range of diagnostic solutions for hepatitis E and other infectious diseases. They have established themselves as key players by continually innovating their testing technologies, expanding their product portfolios, and offering cost-effective solutions to meet the growing demand for hepatitis E diagnostics.

The competitive landscape is also shaped by the increasing entry of new players that focus on providing specialized diagnostic tests and improving the accuracy of results. With advancements in technology, including PCR and immunoassays, these companies are competing to offer faster, more accurate, and more affordable solutions to healthcare providers. As the market continues to expand, ongoing innovations and improvements in testing technologies will be crucial for companies looking to maintain a competitive edge.

Recent Developments:

• In December 2024, Roche Diagnostics launched a new hepatitis E PCR test for faster detection.
• In November 2024, Abbott Laboratories introduced a next-generation immunoassay for hepatitis E virus screening.
• In October 2024, Siemens Healthineers expanded its hepatitis diagnostics portfolio with an ELISA-based test.
• In September 2024, Thermo Fisher Scientific received FDA approval for a new hepatitis E diagnostic kit.
• In August 2024, Hologic partnered with diagnostic labs to implement their new point-of-care testing platform for hepatitis E.

List of Leading Companies:

• Roche Diagnostics
• Abbott Laboratories
• Siemens Healthineers
• Bio-Rad Laboratories
• Hologic
• Cepheid
• Thermo Fisher Scientific
• Alere Inc.
• DiaSorin
• Merck Group
• Becton Dickinson
• Inovio Pharmaceuticals
• GenMark Diagnostics
• Quidel Corporation
• Ortho Clinical Diagnostics

Report Scope: